A comprehensive financial comparison between Eli Lilly and Co. (NYSE: LLY) and Roche Holding AG (OTC: RHHBY), published on 11 June 2026 and covering the fiscal year ending 31 December 2025, shows LLY outperforming RHHBY across most profitability and growth metrics while RHHBY holds the advantage on free cash flow efficiency and dividend yield.

LLY reported a gross profit margin of 83% against RHHBY's 74%, a net profit margin of 32% versus RHHBY's 22%, and an operating margin of 39% compared to RHHBY's 27%. LLY's return on equity of 77.78% significantly exceeds RHHBY's 36.43%, and its return on capital employed of 33.31% compares favourably to RHHBY's 23.35%. However, RHHBY recorded a materially higher free cash flow margin of 20.22%, compared to LLY's 9.15%.

On valuation metrics, LLY trades at a substantial premium. LLY carries a price-to-earnings ratio of 40.2, a price-to-book ratio of 75.84, and an EV/EBITDA of 43.26x. RHHBY, which also trades on the SIX Swiss Exchange under the ticker ROG, carries a price-to-earnings ratio of 19.92, a price-to-book ratio of 22.46, and an EV/EBITDA of 15.45x. RHHBY offers a dividend yield of 3.01% compared to LLY's 0.57%.

RHHBY holds advantages across efficiency metrics. Its asset turnover ratio of 0.63 exceeds LLY's 0.58, its inventory turnover ratio of 2.23 compares to LLY's 0.8, and its receivables turnover ratio of 5.51 is higher than LLY's 3.67. On the other hand, LLY carries a higher debt-to-equity ratio of 160 versus RHHBY's 84.

LLY's five-year free cash flow CAGR of 5.93% trails RHHBY's 27.9%, though LLY's five-year revenue CAGR of 21.58% far exceeds RHHBY's 0.98%. RHHBY's most recent EPS was CHF 16.18 for fiscal 2025, with EPS growth of 55.73%.